September 19, 2012
Five University of California, San Diego graduate students pursuing research at the intersection of bioengineering, medicine and biology are among the 85 recipients of 2013 Siebel Scholars awards, announced by the Siebel Scholars Foundation on September 10, 2012.
August 29, 2019
Nine-month-old brains-in-a-dish and the brains of premature newborn babies generate similar electrical patterns, as captured by electroencephalogram (EEG) — the first time such brain activity has been achieved in a cell-based laboratory model.
July 25, 2024
An experimental cancer drug could ease cognition for individuals with Rett syndrome, a rare disorder linked to autism, according to new research from the Muotri Lab at the University of California San Diego — a discovery that could lead to therapies for patients with other neurologic conditions.
January 16, 2020
Two different UC San Diego research teams identified the same molecule — αvβ5 integrin — as Zika virus’ key to brain cell entry. They found ways to take advantage of the integrin to both block Zika virus from infecting cells and turn it into something good: a way to shrink…
April 6, 2023
After decades of working in industry and academia, biophysicists Alex Savtchenko and Elena Molokanova still have big dreams.
September 16, 2014
Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.
November 17, 2014
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well, report researchers at the University of California, San Diego School of Medicine.
December 21, 2015
Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 and ROR2, to accelerate the proliferation and spread of chronic lymphocytic leukemia (CLL) cells, the…
May 2, 2016
Oncternal Therapeutics, a new cancer-focused biotechnology startup, has signed a wide-ranging licensing agreement with UC San Diego to develop and commercialize antibodies and antibody-related binding agents.
